AIM, ImmunoTech

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

11.02.2026 - 11:13:04

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement of a rights offering today, coinciding with an investor webinar. The central question for stakeholders is whether the targeted capital will be sufficient to advance the company’s lead drug candidate, Ampligen, through its ambitious trial objectives.

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline - Foto: über boerse-global.de
AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline - Foto: über boerse-global.de

Concurrently with the offering, company management is hosting a conference to update investors on clinical progress, particularly for the DURIPANC Phase 2 study. This trial is evaluating Ampligen in combination with AstraZeneca’s immunotherapy drug, Imfinzi, as a treatment for metastatic pancreatic cancer.

Key Clinical Trial Status:
* Patient Recruitment: 18 out of a planned 25 patients have Read more...

@ boerse-global.de | US00901B1052 AIM